Neurogene
NGNE | NASDAQ
$23.30
-$0.63 (-2.63%)
At close: Nov 16, 2026, 4:00 PM ET
$23.30
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Neurogene Company Profile
Company profile explainedCompany Profile
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Rachel L. McMinn | Founder, Executive Chair & Chief Executive Officer |
| Andrew E. Mulberg FAAP | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control |
| Arvind Sreedharan | Senior Vice President of Business Operations |
| Christina Shafer | Chief Commercial Officer |
| Christine Mikail Cvijic | President, CFO & Director |
| Donna Cochener-Metcalfe | Senior Vice President, General Counsel & Corporate Secretary |
| Julie Jordan | Chief Medical Officer |
| Lina Li | Executive Director of Investor Relations |
| Ricardo Jimenez | Senior Vice President of Technical Operations |
| Stuart Cobb | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 06, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 02, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 07, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
Neurogene
| Country | United States |
| IPO Date | Mar 7, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Rachel L. McMinn |
Contact Details
535 W 24th Street New York City,
New York 10011 United States
Stock Details
| Ticker Symbol | NGNE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001404644 |
| CUSIP Number | 64135M105 |
| ISIN Number | US64135M1053 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove NGNE